Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass

Se Young Oh, Jong Chan Kim, Yong Seon Choi, Woo Kyung Lee, Yeong Kyu Lee, Younglan Kwak

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB). Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU arrival, and on POD 1. Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal injury between the two groups at any point during the study period. Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve replacement.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalKorean Journal of Anesthesiology
Volume62
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Cardiopulmonary Bypass
Aortic Valve
Kidney
Wounds and Injuries
MB Form Creatine Kinase
Ambulatory Surgical Procedures
Therapeutics
Anesthesia
Cystatin C
Control Groups
urinastatin
Weaning
Serum
Intensive Care Units
Creatinine
Biomarkers

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

Cite this

Oh, Se Young ; Kim, Jong Chan ; Choi, Yong Seon ; Lee, Woo Kyung ; Lee, Yeong Kyu ; Kwak, Younglan. / Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. In: Korean Journal of Anesthesiology. 2012 ; Vol. 62, No. 2. pp. 148-153.
@article{f8fa4fd08e054d6c84e3f7844f6c1f78,
title = "Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass",
abstract = "Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB). Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU arrival, and on POD 1. Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal injury between the two groups at any point during the study period. Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve replacement.",
author = "Oh, {Se Young} and Kim, {Jong Chan} and Choi, {Yong Seon} and Lee, {Woo Kyung} and Lee, {Yeong Kyu} and Younglan Kwak",
year = "2012",
month = "2",
day = "1",
doi = "10.4097/kjae.2012.62.2.148",
language = "English",
volume = "62",
pages = "148--153",
journal = "Korean Journal of Anesthesiology",
issn = "2005-6419",
publisher = "Korean Society of Anesthesiologists",
number = "2",

}

Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. / Oh, Se Young; Kim, Jong Chan; Choi, Yong Seon; Lee, Woo Kyung; Lee, Yeong Kyu; Kwak, Younglan.

In: Korean Journal of Anesthesiology, Vol. 62, No. 2, 01.02.2012, p. 148-153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass

AU - Oh, Se Young

AU - Kim, Jong Chan

AU - Choi, Yong Seon

AU - Lee, Woo Kyung

AU - Lee, Yeong Kyu

AU - Kwak, Younglan

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB). Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU arrival, and on POD 1. Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal injury between the two groups at any point during the study period. Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve replacement.

AB - Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB). Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU arrival, and on POD 1. Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal injury between the two groups at any point during the study period. Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve replacement.

UR - http://www.scopus.com/inward/record.url?scp=84863291732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863291732&partnerID=8YFLogxK

U2 - 10.4097/kjae.2012.62.2.148

DO - 10.4097/kjae.2012.62.2.148

M3 - Article

VL - 62

SP - 148

EP - 153

JO - Korean Journal of Anesthesiology

JF - Korean Journal of Anesthesiology

SN - 2005-6419

IS - 2

ER -